Gubra A/S - Asset Resilience Ratio
Gubra A/S (GUBRA) has an Asset Resilience Ratio of 79.61% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Gubra A/S's Asset Resilience Ratio has changed over time. See Gubra A/S leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Gubra A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GUBRA company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr1.05 Billion | 79.61% |
| Total Liquid Assets | Dkr1.05 Billion | 79.61% |
Asset Resilience Insights
- Very High Liquidity: Gubra A/S maintains exceptional liquid asset reserves at 79.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Gubra A/S Industry Peers by Asset Resilience Ratio
Compare Gubra A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896 |
Biotechnology | 12.69% |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399 |
Biotechnology | 37.23% |
Annual Asset Resilience Ratio for Gubra A/S (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Gubra A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 79.61% | Dkr1.05 Billion ≈ $164.40 Million |
Dkr1.32 Billion ≈ $206.50 Million |
+32.62pp |
| 2024-12-31 | 47.00% | Dkr287.84 Million ≈ $45.03 Million |
Dkr612.48 Million ≈ $95.83 Million |
-17.61pp |
| 2023-12-31 | 64.61% | Dkr403.99 Million ≈ $63.21 Million |
Dkr625.28 Million ≈ $97.83 Million |
-- |
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for th… Read more